



28 June 2024

Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")

Result of AGM
Change of Name of Nominated Adviser and Joint Broker

Cambridge Cognition plc (AIM: COG), which develops and markets digital solutions to assess brain health, held its Annual General Meeting ("AGM") earlier today at the registered office of the Company; Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU and announces that all resolutions put forward were duly passed.

Proxy votes were received in respect of approximately 55% of the Company's issued share capital and the votes cast were as follows:

<i>Resolution</i>	<i>For</i>		<i>Against</i>		<i>Withheld</i>
1 - to approve the 2023 report and accounts	22,321,648	99.98%	5,003	0.02%	642,810
2 - to appoint the auditors	22,930,519	99.96%	8,503	0.04%	30,439
3 - to authorise the directors to set the auditors remuneration	22,942,198	99.98%	5,003	0.02%	22,260
4 - to re-elect Richard Bungay as a director	20,756,611	98.92%	226,842	1.08%	1,986,008
5 - to elect Nick Rodgers as a director	22,927,961	99.82%	40,492	0.18%	1,008
6 - to elect Stuart Gall as a director	22,927,961	99.82%	40,492	0.18%	1,008
7 - authority to allot shares	22,798,499	99.26%	169,954	0.74%	1,008
8 - disapplication of pre-emption rights	22,789,981	99.22%	178,472	0.78%	1,008
9 - disapplication of pre-emption rights in connection with an acquisition or specified capital investment	22,788,299	99.22%	180,154	0.78%	1,008

Change of Name of Nominated Adviser and Broker

The Company also announces that its Nominated Adviser and Joint Broker has changed its name to Panmure Liberum Limited following completion of its own corporate merger.

Enquiries

Cambridge Cognition Holdings plc
Matthew Stork, Chief Executive Officer
Stephen Symonds, Chief Financial Officer

www.cambridgecognition.com
Tel: 01223 810 700

Panmure Liberum Limited (NOMAD & Joint Broker)
Freddy Crossley / Emma Earl / Mark Rogers
Rupert Dearden

Tel: 020 78862500
(Corporate Advisory)
(Corporate Broking)

Dowgate Capital Limited (Joint Broker)
David Poutney / James Serjeant

Tel: 020 3903 7715
(Corporate Broking)

Hudson Sandler (Financial PR and IR)
Dan de Belder / Hattie Dreyfus

Tel: 020 7796 4133

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company marketing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGDZGZVZRNGDZM